In 2023, Germany led the Global Obstructive Airway Diseases Medicine Sales with $3.1 billion, followed by Canada at $1.66 billion, and Croatia at $0.5446 billion. Austria, Sweden, and Chile showed moderate sales of $0.2506 billion, $0.2469 billion, and $0.2147 billion respectively. Ireland, Latvia, and Iceland reported lower sales, with Ireland at $0.1235 billion, Latvia at $0.0208 billion, and Iceland at $0.0126 billion. Notably, Chile experienced the highest year-on-year variation in 2023 at 7.52%, while Iceland saw a significant increase of 6.72%. Ireland was the only country with a negative variation of -0.79%.
Future trends to watch for in the Global Obstructive Airway Diseases Medicine Sales include the impact of advancing medical treatments and technology on sales patterns, particularly in high-growth areas such as Chile and Iceland. Economic and healthcare policy changes in key markets like Germany and Canada will also play crucial roles in shaping the market. Additionally, monitoring the development of new drugs and their market penetration will be essential for forecasting long-term sales growth.
Top countries in Obstructive Airway Diseases Medicine Sales by Country
| # | 9 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 3,100 | 2023 | +2.3% | +3.69% | View data |
| 2 | 2 Canada | 1,660 | 2023 | +0.86% | +3.37% | View data |
| 3 | 3 Croatia | 544.6 | 2023 | +1.13% | +1.61% | View data |
| 4 | 4 Austria | 250.6 | 2023 | +2.83% | +4.32% | View data |
| 5 | 5 Sweden | 246.9 | 2023 | +0.73% | +3.9% | View data |
| 6 | 6 Chile | 214.7 | 2023 | +6.18% | +7.52% | View data |
| 7 | 7 Ireland | 123.5 | 2023 | -1.75% | -0.79% | View data |
| 8 | 8 Latvia | 20.8 | 2023 | -0.95% | +1.51% | View data |
| 9 | 9 Iceland | 12.6 | 2023 | +1.61% | +6.72% | View data |
